UBS Maintains Buy on Ascendis Pharma, Raises Price Target to $315
Benzinga Newsdesk 9 hours ago
Analyst RatingsNewsPrice Target
UBS analyst Joon Lee maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $269 to $315.
UBS analyst Joon Lee maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $269 to $315.